[PDF][PDF] Apixaban in Patients with Atrial Fibrillation and Severe Renal Dysfunction: Findings from a National Registry
MD Avishay Elis, MD Robert Klempfner… - ima-files.s3.amazonaws.com
Background: Real-world information regarding the use of direct oral anticoagulants therapy
and the outcome in patients with renal dysfunction is limited. Objectives: To evaluate the …
and the outcome in patients with renal dysfunction is limited. Objectives: To evaluate the …
The possibilities of therapeutic intervention and prevention of cerebrovascular complications in atrial fibrillation in patients on program hemodialysis
IT Murkamilov, IS Sabirov, VV Fomin… - Clinical …, 2019 - modernonco.orscience.ru
The article is devoted to the important interdisciplinary problem-atrial fibrillation (AF) and the
risk of cerebrovascular complications (CVCs) in patients on program hemodialysis (PhD) …
risk of cerebrovascular complications (CVCs) in patients on program hemodialysis (PhD) …
Apixaban preferred choice in AF irrespective of kidney function
SM Altawalbeh - PharmacoEconomics & Outcomes News, 2018 - Springer
Apixaban is more effective and less costly than warfarin in patients with atrial fibrillation (AF)
and chronic kidney disease (CKD), and cost effective in those with AF and normal kidney …
and chronic kidney disease (CKD), and cost effective in those with AF and normal kidney …